ProCE Banner Activity

Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
This open-label, multicenter, dose-finding phase Ib trial suggests that subcutaneous daratumumab plus rHuPH20 is safe and effective in patients with relapsed/refractory MM.

Released: December 07, 2016

Expiration: December 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen